Hefei Everlife Pharmaceutical

Hefei Everlife Pharmaceutical, also known as Hefei Hengsheng Pharmaceutical, is a Chinese biopharmaceutical company and a subsidiary of Hefei Lifeon Pharmaceutical. The company is primarily recognized for its development of Uroacitides (CDA-II), a therapeutic agent extracted from human urine that is approved in China for the treatment of Myelodysplastic Syndromes (MDS). Beyond its flagship product, the company focuses on oncology and hematology, investigating Uroacitides for additional indications such as breast cancer and non-small cell lung cancer. As part of the Hefei Lifeon group, Hefei Everlife benefits from integrated R&D and manufacturing capabilities located in the Hefei High-tech Industrial Development Zone.